Moderna
MRNA
#278
Rank
NZ$150.57 B
Marketcap
NZ$372.15
Share price
2.59%
Change (1 day)
764.10%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

Moderna (MRNA) - Total debt

Total debt on the balance sheet as of June 2026 : NZ$2.34 Billion

According to Moderna 's latest financial reports the company's total debt is NZ$2.34 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Moderna - Total debt on balance sheet (from 2017 to 2026)

Total debt by year

Year Total debt Change
2025-12-31NZ$2.25 B70.12%
2024-12-31NZ$1.32 B-32.61%
2023-12-31NZ$1.96 B3.99%
2022-12-31NZ$1.89 B40.94%
2021-12-31NZ$1.34 B308.28%
2020-12-31NZ$0.32 B67.13%
2019-12-31NZ$0.19 B293.66%
2018-12-31NZ$49.92 M126.03%
2017-12-31NZ$22.08 M22.4%
2016-12-31NZ$18.04 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Johnson & Johnson
JNJ
NZ$81.25 B 3,369.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
NZ$87.91 B 3,653.69%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Merck
MRK
NZ$98.09 B 4,088.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ$2.54 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ$33.8 M-98.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
NZ$2.29 B-1.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Arrowhead Pharmaceuticals
ARWR
NZ$1.79 B-23.57%๐Ÿ‡บ๐Ÿ‡ธ USA